Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled…

Overview of attention for article published in Diabetes Therapy, June 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet
policy: 2 policy sources

twitter: 1 X user

Readers on

mendeley: 117 Mendeley

Summary News Policy documents X

So far, Altmetric has seen 2 policy documents that reference this research output.

Dapagliflozin

Cited by Canadian Agency for Drugs and Technologies in Health on 07 Sep 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Type 2 diabetes in adults: management : March 2018: evidence reviews for SGLT-2 inhibitors and GLP-1 mimetics

Cited by National Institute for Health and Care Excellence on 05 Mar 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.